Event-driven risks are pervasive in the health care industry, with the most notable being FDA approval decisions for prospective drugs or medical devices. For medical technology company Cyberonics (NASDAQ: CYBX ) , event-driven risk was a bit different. The company -- which already has a neuro-stimulation device approved and on the market -- has been dealing with the dark cloud of a serious lawsuit brought on by a former employee.
Today, that cloud was lifted when the suit was voluntarily dismissed, and shares are surging higher as a result. However, as Brenton Flynn discusses in the video below, the company has plenty of additional obstacles to overcome as it looks to justify a premium valuation.
Another medical devices company looking to surge higher is MAKO Surgical. The recent market sell-off in shares has many wondering whether the potential growth prospects of the robotic surgery company make it a buy or a name to stay away from. To answer this question, Fool.com analyst and MAKO expert David Meier has authored a premium research report covering all of the must-know details on the company, including key areas to watch and risks looming in the future. As an added bonus, David will keep you informed with a full year of updates and guidance on MAKO Surgical as news breaks. Click here now to learn more and start reading.